Seelos Therapeutics Current Ratio 2010-2022 | SEEL
Seelos Therapeutics current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Seelos Therapeutics Current Ratio Historical Data |
Date |
Current Assets |
Current Liabilities |
Current Ratio |
2022-03-31 |
$0.07B |
$0.01B |
6.98 |
2021-12-31 |
$0.08B |
$0.01B |
10.07 |
2021-09-30 |
$0.08B |
$0.01B |
10.07 |
2021-06-30 |
$0.09B |
$0.01B |
11.88 |
2021-03-31 |
$0.04B |
$0.01B |
3.10 |
2020-12-31 |
$0.02B |
$0.01B |
2.36 |
2020-09-30 |
$0.01B |
$0.00B |
3.48 |
2020-06-30 |
$0.01B |
$0.00B |
2.09 |
2020-03-31 |
$0.01B |
$0.01B |
1.97 |
2019-12-31 |
$0.01B |
$0.01B |
1.03 |
2019-09-30 |
$0.02B |
$0.01B |
2.93 |
2019-06-30 |
$0.01B |
$0.00B |
2.42 |
2019-03-31 |
$0.01B |
$0.01B |
2.54 |
2018-12-31 |
$0.00B |
$0.01B |
0.04 |
2018-09-30 |
$0.01B |
$0.00B |
3.85 |
2018-06-30 |
$0.01B |
$0.00B |
3.75 |
2018-03-31 |
$0.01B |
$0.00B |
3.50 |
2017-12-31 |
$0.01B |
$0.00B |
4.16 |
2017-09-30 |
$0.01B |
$0.00B |
4.79 |
2017-06-30 |
$0.01B |
$0.00B |
4.69 |
2017-03-31 |
$0.01B |
$0.00B |
1.99 |
2016-12-31 |
$0.00B |
$0.01B |
0.32 |
2016-09-30 |
$0.01B |
$0.01B |
0.57 |
2016-06-30 |
$0.01B |
$0.01B |
0.37 |
2016-03-31 |
$0.01B |
$0.01B |
0.69 |
2015-12-31 |
$0.01B |
$0.02B |
0.40 |
2015-09-30 |
$0.01B |
$0.01B |
1.19 |
2015-06-30 |
$0.01B |
$0.01B |
1.97 |
2015-03-31 |
$0.02B |
$0.01B |
2.52 |
2014-12-31 |
$0.01B |
$0.01B |
1.92 |
2014-09-30 |
$0.02B |
$0.01B |
2.88 |
2014-06-30 |
$0.02B |
$0.01B |
2.70 |
2014-03-31 |
$0.02B |
$0.02B |
1.62 |
2013-12-31 |
$0.02B |
$0.01B |
1.89 |
2013-09-30 |
$0.02B |
$0.01B |
2.58 |
2013-06-30 |
$0.03B |
$0.01B |
2.39 |
2013-03-31 |
$0.02B |
$0.01B |
1.53 |
2012-12-31 |
$0.02B |
$0.01B |
1.94 |
2012-09-30 |
$0.03B |
$0.02B |
1.81 |
2012-06-30 |
$0.02B |
$0.01B |
1.82 |
2012-03-31 |
$0.02B |
$0.01B |
2.34 |
2011-12-31 |
$0.01B |
$0.01B |
0.82 |
2011-09-30 |
$0.01B |
$0.00B |
3.25 |
2011-06-30 |
$0.01B |
$0.00B |
2.55 |
2011-03-31 |
$0.01B |
$0.00B |
4.51 |
2010-12-31 |
$0.01B |
$0.00B |
4.53 |
2010-09-30 |
$0.00B |
|
0.00 |
2010-06-30 |
$0.01B |
$0.00B |
2.17 |
2010-03-31 |
$0.00B |
$0.01B |
0.27 |
2009-12-31 |
$0.00B |
$0.01B |
0.12 |
2009-09-30 |
$0.00B |
$0.00B |
3.67 |
2009-06-30 |
$0.00B |
$0.00B |
2.90 |
2009-03-31 |
$0.00B |
$0.00B |
4.22 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.067B |
$0.000B |
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
|